538 related articles for article (PubMed ID: 26536370)
1. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
3. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
4. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
Rusthoven CG; Yeh N; Gaspar LE
Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
6. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
Guerrero E; Ahmed M
Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
[TBL] [Abstract][Full Text] [Related]
7. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
8. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.
Westover KD; Iyengar P; Sharma AN; Timmerman R
Lung Cancer; 2015 Aug; 89(2):87-93. PubMed ID: 26028304
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy for oligometastatic non-small cell lung cancer.
Salama JK; Schild SE
Cancer Metastasis Rev; 2015 Jun; 34(2):183-93. PubMed ID: 25948377
[TBL] [Abstract][Full Text] [Related]
10. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
Bansal P; Rusthoven C; Boumber Y; Gan GN
Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
[TBL] [Abstract][Full Text] [Related]
11. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
Shultz DB; Diehn M; Loo BW
Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U
J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641
[TBL] [Abstract][Full Text] [Related]
13. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.
Ashworth AB; Senan S; Palma DA; Riquet M; Ahn YC; Ricardi U; Congedo MT; Gomez DR; Wright GM; Melloni G; Milano MT; Sole CV; De Pas TM; Carter DL; Warner AJ; Rodrigues GB
Clin Lung Cancer; 2014 Sep; 15(5):346-55. PubMed ID: 24894943
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and management of oligometastatic non-small cell lung cancer.
Patel AN; Simone CB; Jabbour SK
Ther Adv Respir Dis; 2016 Aug; 10(4):338-48. PubMed ID: 27060187
[TBL] [Abstract][Full Text] [Related]
16. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
18. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
20. Local Therapy Indications in the Management of Patients with Oligometastatic Non-Small Cell Lung Cancer.
Miller DA; Krasna MJ
Surg Oncol Clin N Am; 2016 Jul; 25(3):611-20. PubMed ID: 27261919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]